Steven Pascoe
About
Steven Pascoe is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Genetics.
According to data from OpenAlex, Steven Pascoe has authored 49 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Pulmonary and Respiratory Medicine, 38 papers in Physiology and 2 papers in Genetics. Recurrent topics in Steven Pascoe's work include Asthma and respiratory diseases (38 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (31 papers) and Respiratory and Cough-Related Research (16 papers). Steven Pascoe is often cited by papers focused on Asthma and respiratory diseases (38 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (31 papers) and Respiratory and Cough-Related Research (16 papers). Steven Pascoe collaborates with scholars based in United Kingdom, United States and Denmark. Steven Pascoe's co-authors include Mark T. Dransfield, Neil Barnes, Ian Pavord, Nicholas Locantore, David A. Lipson, David A. Lomas, Maggie Tabberer, Noushin Brealey, Dave Singh and Robert A. Wise and has published in prestigious journals such as New England Journal of Medicine, American Journal of Respiratory and Critical Care Medicine and CHEST Journal.
In The Last Decade
Steven Pascoe
47 papers receiving 2.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Steven Pascoe United Kingdom | 17 | 2.5k | 2.1k | 186 | 85 | 78 | 49 | 2.7k | ||
| Frank Barnhart United States | 7 | 1.2k 0.5× | 900 0.4× | 66 0.4× | 56 0.7× | 48 0.6× | 15 | 1.3k | ||
| Cynthia Caracta United States | 21 | 1.4k 0.5× | 1.2k 0.6× | 28 0.2× | 53 0.6× | 64 0.8× | 92 | 1.7k | ||
| R. Escamilla France | 18 | 779 0.3× | 430 0.2× | 84 0.5× | 222 2.6× | 69 0.9× | 62 | 1.1k | ||
| Claudio Micheletto Italy | 20 | 816 0.3× | 802 0.4× | 89 0.5× | 50 0.6× | 48 0.6× | 104 | 1.3k | ||
| Joseph C. Kidney United Kingdom | 17 | 707 0.3× | 470 0.2× | 107 0.6× | 261 3.1× | 141 1.8× | 32 | 1.1k | ||
| Carin Jorup Sweden | 16 | 1.8k 0.7× | 1.9k 0.9× | 64 0.3× | 48 0.6× | 53 0.7× | 32 | 2.1k | ||
| Stanislav Šuškovič Slovenia | 14 | 388 0.2× | 340 0.2× | 64 0.3× | 59 0.7× | 61 0.8× | 25 | 863 | ||
| RA Jörres Germany | 15 | 669 0.3× | 371 0.2× | 42 0.2× | 62 0.7× | 31 0.4× | 34 | 842 | ||
| Claudio M. Sanguinetti Italy | 15 | 524 0.2× | 237 0.1× | 51 0.3× | 106 1.2× | 49 0.6× | 55 | 692 | ||
| R A Primhak United Kingdom | 19 | 712 0.3× | 401 0.2× | 118 0.6× | 104 1.2× | 50 0.6× | 35 | 996 |
Countries citing papers authored by Steven Pascoe
Since
Specialization
Citations
This map shows the geographic impact of Steven Pascoe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven Pascoe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven Pascoe more than expected).
Fields of papers citing papers by Steven Pascoe
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Steven Pascoe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven Pascoe. The network helps show where Steven Pascoe may publish in the future.
Co-authorship network of co-authors of Steven Pascoe
This figure shows the co-authorship network connecting the top 25 collaborators of Steven Pascoe. A scholar is included among the top collaborators of Steven Pascoe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven Pascoe. Steven Pascoe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Lipson, David A., Courtney Crim, Gerard J. Criner, et al.. (2020). Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 201(12). 1508–1516.
2.
Lee, Laurie A., Zelie Bailes, Neil Barnes, et al.. (2020). Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. The Lancet Respiratory Medicine. 9(1). 69–84.
3.
Kerwin, Edward, Steven Pascoe, Zelie Bailes, et al.. (2020). A phase IIb, randomised, parallel-group study: the efficacy, safety and tolerability of once-daily umeclidinium in patients with asthma receiving inhaled corticosteroids. Respiratory Research. 21(1). 148–148.
4.
Patel, Mehul S., et al.. (2019). Anaemia and iron dysregulation: untapped therapeutic targets in chronic lung disease?. BMJ Open Respiratory Research. 6(1). e000454–e000454.
5.
Pascoe, Steven, Neil Barnes, Guy Brusselle, et al.. (2019). Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. The Lancet Respiratory Medicine. 7(9). 745–756.
6.
Nelsen, Linda, Laurie A. Lee, Wei Wu, et al.. (2019). Reliability, validity and responsiveness of E-RS:COPD in patients with spirometric asthma-COPD overlap. Respiratory Research. 20(1). 107–107.
7.
Pascoe, Steven, et al.. (2018). Use of clinical characteristics to predict spirometric classification of obstructive lung disease. International Journal of COPD. Volume 13. 889–902.
8.
Nelsen, Linda, et al.. (2018). Understanding and measuring symptoms and health status in asthma COPD overlap: content validity of the EXACT and SGRQ. Journal of Patient-Reported Outcomes. 2(1). 18–18.
9.
Siddiqui, Salman, Ian Pavord, Neil Barnes, et al.. (2018). Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids. International Journal of COPD. Volume 13. 3669–3676.
10.
Kerwin, Edward, et al.. (2017). The effect of umeclidinium on lung function and symptoms in patients with fixed airflow obstruction and reversibility to salbutamol: A randomised, 3-phase study. Respiratory Medicine. 131. 148–157.
11.
Lipson, David A., Helen Barnacle, Ruby Birk, et al.. (2017). FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 196(4). 438–446.
12.
Pascoe, Steven, et al.. (2017). Biological effects of p38 MAPK inhibitor losmapimod does not translate to clinical benefits in COPD. Respiratory Medicine. 130. 20–26.
13.
Hinds, David, Rachael L. DiSantostefano, Hoa Le, & Steven Pascoe. (2016). Identification of responders to inhaled corticosteroids in a chronic obstructive pulmonary disease population using cluster analysis. BMJ Open. 6(6). e010099–e010099.
14.
Pascoe, Steven, David A. Lipson, Nicholas Locantore, et al.. (2016). A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol. European Respiratory Journal. 48(2). 320–330.
15.
Stempel, David A., Stanley J. Szefler, Søren Pedersen, et al.. (2016). Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma. New England Journal of Medicine. 375(9). 840–849.
16.
Marks-Kończalik, Joanna, et al.. (2015). A post-hoc subgroup analysis of data from a six month clinical trial comparing the efficacy and safety of losmapimod in moderate-severe COPD patients with ≤2% and >2% blood eosinophils. Respiratory Medicine. 109(7). 860–869.
17.
Pascoe, Steven, Nicholas Locantore, Mark T. Dransfield, Neil Barnes, & Ian Pavord. (2015). Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. The Lancet Respiratory Medicine. 3(6). 435–442.
18.
Pascoe, Steven, et al.. (2014). Late-breaking abstract: Blood eosinophil count as a biomarker of ICS effectiveness in reducing exacerbation rates in COPD. European Respiratory Journal. 44(Suppl 58). P2817–P2817.
19.
Barst, Robyn J., Hossein Ardeschir Ghofrani, Nicholas W. Morrell, et al.. (2009). IMATINIB MESYLATE TREATMENT FOR SEVERE PULMONARY ARTERIAL HYPERTENSION: A PROPOSED PHASE III 24-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED CLINICAL TRIAL. CHEST Journal. 136(4). 64S–64S.
20.
Beier, Jutta, Kai Michael Beeh, L Brookman, et al.. (2009). Bronchodilator effects of indacaterol and formoterol in patients with COPD. Pulmonary Pharmacology & Therapeutics. 22(6). 492–496.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Frank Barnhart Breakdown of academic impact, for papers by Cynthia Caracta Breakdown of academic impact, for papers by R. Escamilla Breakdown of academic impact, for papers by Claudio Micheletto Breakdown of academic impact, for papers by Joseph C. Kidney Breakdown of academic impact, for papers by Carin Jorup Breakdown of academic impact, for papers by Stanislav Šuškovič Breakdown of academic impact, for papers by RA Jörres Breakdown of academic impact, for papers by Claudio M. Sanguinetti Breakdown of academic impact, for papers by R A Primhak